These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 15300150)

  • 1. Integrating basic science and clinical research in bladder cancer: update from the first bladder Specialized Program of Research Excellence (SPORE).
    Highshaw RA; McConkey DJ; Dinney CP
    Curr Opin Urol; 2004 Sep; 14(5):295-300. PubMed ID: 15300150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family.
    Bellmunt J; Hussain M; Dinney CP
    Crit Rev Oncol Hematol; 2003 Jun; 46 Suppl():S85-104. PubMed ID: 12850530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ZD1839: targeting the epidermal growth factor receptor in cancer therapy.
    Herbst RS
    Expert Opin Investig Drugs; 2002 Jun; 11(6):837-49. PubMed ID: 12036427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptor inhibitors: a new prospective in the treatment of lung cancer.
    Tiseo M; Loprevite M; Ardizzoni A
    Curr Med Chem Anticancer Agents; 2004 Mar; 4(2):139-48. PubMed ID: 15032719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overview of bladder cancer trials in the Cancer and Leukemia Group B.
    Small EJ; Halabi S; Dalbagni G; Pruthi R; Phillips G; Edelman M; Bajorin D;
    Cancer; 2003 Apr; 97(8 Suppl):2090-8. PubMed ID: 12673701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted therapies in bladder cancer--an update.
    Black PC; Agarwal PK; Dinney CP
    Urol Oncol; 2007; 25(5):433-8. PubMed ID: 17826665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of EGFR inhibitors in nonsmall cell lung cancer.
    Ciardiello F; De Vita F; Orditura M; Tortora G
    Curr Opin Oncol; 2004 Mar; 16(2):130-5. PubMed ID: 15075904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC.
    Langer CJ
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):991-1002. PubMed ID: 14967461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Anti-ErbB targeted therapy and urothelial tumors].
    Amsellem-Ouazana D; Goldwasser F; Bieche I; Lidereau R; Zerbib M
    Prog Urol; 2005 Dec; 15(6 Suppl 1):1229-35. PubMed ID: 16734210
    [No Abstract]   [Full Text] [Related]  

  • 10. Chemotherapy of advanced transitional-cell carcinoma of the bladder.
    Miller RS; Torti FM
    Cancer Chemother Pharmacol; 1992; 30 Suppl():S99-110. PubMed ID: 1394829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers.
    Herbst RS; Langer CJ
    Semin Oncol; 2002 Feb; 29(1 Suppl 4):27-36. PubMed ID: 11894011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant chemotherapy for invasive urothelial cancer: experience with a methotrexate, vincristine, cisplatin, cyclophosphamide, adriamycin and bleomycin (MVP-CAB) regimen: a preliminary report.
    Gohji K; Higuchi A; Maruyama S; Minayoshi K; Fujii A; Itoh N; Hasunuma Y; Tanaka H; Izumi T
    Jpn J Clin Oncol; 1993 Oct; 23(5):291-8. PubMed ID: 7693990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on chemotherapy for advanced bladder cancer.
    Rosenberg JE; Carroll PR; Small EJ
    J Urol; 2005 Jul; 174(1):14-20. PubMed ID: 15947569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-epidermal growth factor receptor drugs in cancer therapy.
    Ciardiello F; Tortora G
    Expert Opin Investig Drugs; 2002 Jun; 11(6):755-68. PubMed ID: 12036420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients.
    Herbst RS
    Semin Oncol; 2003 Feb; 30(1 Suppl 1):30-8. PubMed ID: 12644982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The epidermal growth factor receptor pathway and its inhibition as anticancer therapy.
    Janmaat ML; Giaccone G
    Drugs Today (Barc); 2003; 39 Suppl C():61-80. PubMed ID: 14988746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.
    Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Hockenhull J; Proudlove C; Dundar Y; Richardson M; Dickson R; Mullard A; Marshall E
    Health Technol Assess; 2015 Jun; 19(47):1-134. PubMed ID: 26134145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of a new combined primary chemotherapy regimen, intravenous methotrexate and vincristine and intraarterial adriamycin and cisplatin, for locally advanced urinary bladder cancer: preliminary results.
    Kuroiwa T; Naito S; Hasuo K; Kishikawa T; Masuda K; Kumazawa J
    Cancer Chemother Pharmacol; 1995; 35(5):357-63. PubMed ID: 7850915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells.
    Kassouf W; Dinney CP; Brown G; McConkey DJ; Diehl AJ; Bar-Eli M; Adam L
    Cancer Res; 2005 Nov; 65(22):10524-35. PubMed ID: 16288045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination treatment with ionising radiation and gefitinib ('Iressa', ZD1839), an epidermal growth factor receptor (EGFR) inhibitor, significantly inhibits bladder cancer cell growth in vitro and in vivo.
    Colquhoun AJ; Mchugh LA; Tulchinsky E; Kriajevska M; Mellon JK
    J Radiat Res; 2007 Sep; 48(5):351-60. PubMed ID: 17609586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.